News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

NovaBiotics Ltd Shortlisted For The Grampian Award For Innovation

4/23/2014 9:52:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Aberdeen, UK – 23 April 2014 – NovaBiotics Ltd, the Aberdeen-based, clinical-stage biotechnology company (“NovaBiotics” or the “Company”), today announced it has been shortlisted for The Grampian Award for Innovation at the 2014 Grampian Awards for Business Excellence which will be held on the 26th of June at the Mercure Aberdeen Ardoe House Hotel.

The Grampian Award for Innovation is awarded to an individual or a business that demonstrates innovation at the core of their current or future success. The winner will be able to clearly articulate the innovative steps they have taken and how the resulting products or services have disrupted the current marketplace or have the potential to do so.

NovaBiotics was shortlisted for its ground-breaking R&D in the anti-infective space which could meet the needs of patients worldwide. NovaBiotics is leveraging its peptide technology platform and drug design expertise to generate a totally novel class of antimicrobial therapies that not only have the potential to meet the need for safer, more effective antifungal and antibacterial treatments but also have no or very low risk of drug resistance development.

Dr Deborah O’Neil said: “The North East is populated with outstanding entrepreneurs and businesses and NovaBiotics is delighted to be recognised for its innovative work by being put through to the final stage of the Awards.” The 2014 Grampian Awards for Business Excellence, hosted by Enterprise North East Trust, take place each year and commend enterprise by selecting and rewarding entrepreneurial companies and individuals that are capable of leading the future prosperity of Grampian.

About NovaBiotics

NovaBiotics is developing novel antifungal and antibacterial therapeutics that have the ability to treat a range of poorly served and clinically challenging infections. The mechanism of action of NovaBiotics’ drug candidates minimises or negates the chance of drug resistance developing in the target microbes/infections which they have been designed to treat. NovaBiotics’ antifungal and antibacterials are not toxic to human cells at therapeutic doses unlike many conventional antimicrobial medications. NovaBiotics’ lead clinical programme is Novexatin®. In addition to Novexatin®, the Company is developing Lynovex®, an antibacterial-mucolytic therapeutic candidate for cystic fibrosis (CF) that is expected to enter a Phase IIa study in Q2 2014; Novamycin®, a peptide antifungal agent against Candida and Aspergillus; and Novarifyn®, a peptide antibacterial for difficult to treat multi-drug resistant Gram-negative and Gram-positive infections, including MRSA. Further information is available at

Issued for and on behalf of NovaBiotics by Instinctif Partners.
For more information please contact:
Dr. Deborah O’Neil - CEO of NovaBiotics
Bryan Bodek - Chairman
+44 (0) 1224 711377
For media enquiries:
Instinctif Partners:
Melanie Toyne Sewell/Stefanie Bacher/Gemma Howe
Tel: +44 (0) 20 7457 2020

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus